APICA (N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide; also known as 2NE1 and SDB-001) is a synthetic cannabinoid receptor agonist belonging to the indole carboxamide class. It is structurally characterized by an indole core linked to a carboxamide with an adamantyl (adamantane) head group and a pentyl alkyl chain. APICA acts as a full agonist at both CB1 and CB2 receptors, with potency in the same range as JWH-018 and substantially greater than THC.
APICA appeared in research chemical and synthetic cannabinoid markets in the early 2010s, typically found in herbal smoking products. Like all potent full-agonist synthetic cannabinoids, APICA carries a substantially elevated risk profile compared to cannabis — seizures, acute psychosis, cardiovascular toxicity, and documented fatalities have been attributed to synthetic cannabinoid products containing indole carboxamide class compounds. The adamantyl head group is shared with several other synthetic cannabinoids and is associated with high CB1/CB2 potency relative to simpler alkyl groups.
Safety at a Glance
High Risk- Avoid Synthetic Cannabinoids
- The safest harm-reduction position is complete avoidance of synthetic cannabinoid products. If harm reduction for use...
- Toxicity: Full Agonist Toxicity APICA shares the full synthetic cannabinoid toxicity profile: cardiovascular events (tachycardi...
- Overdose risk: Fatal overdose from natural cannabis (THC) alone has not been documented. However, synthetic cann...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
smoked
Duration
smoked
Total: 30 min – 1 hrsHow It Feels
APICA delivers a cannabinoid experience with a sharp, focused onset that cuts through consciousness like a blade. Seconds after inhalation, a tightness grips the head -- not painful exactly, but insistent, a pressure that announces the compound's arrival with none of the gentle warmth that natural cannabis typically provides as a prelude. The eyes feel strained, as though someone has turned up the brightness on the visual field without adjusting the contrast. A metallic taste may linger on the tongue.
The high develops quickly into a state that occupies uneasy territory between cannabis-like intoxication and something harder to categorize. There is sedation, but it carries a rigid quality, the body growing heavy and still without the melting, comfortable surrender that characterizes indica strains. The muscles tighten subtly rather than release. The jaw clenches. There is a synthetic stiffness to the physical state, as though the body has been locked into a position of rest rather than invited into one.
Mentally, APICA produces a fragmented, loop-prone cognitive state. Thoughts repeat without progression, circling back to the same observation or sensation with mechanical persistence. Short-term memory is severely impaired, making conversation difficult and sustained reasoning nearly impossible. There is a dissociative quality that separates you from your emotional responses -- events register intellectually but fail to produce proportional feelings, as though the connection between perception and affect has been partially severed. Time slows to an excruciating crawl, each moment dense and overlong.
The sensory shifts are sharp-edged and unsettling. Colors appear vivid but with an artificial quality, as though they have been digitally enhanced. Sounds may become distorted, gaining echoes or harmonic overtones that were not present in the original stimulus. There is a heightened sensitivity to physical sensation that is not always pleasant -- textures feel exaggerated, temperature shifts register with unusual intensity, and the heartbeat becomes a prominent, sometimes alarming presence in the chest.
The duration is one to two hours for primary effects, though the decline can leave residual effects -- foggy thinking, mild anxiety, headache -- for several hours beyond. The comedown has a draining quality, the sharp-edged high giving way to a flat exhaustion that feels like it has been purchased at the cost of the preceding hour's intensity. Appetite may surge or crater. Sleep is achievable but often shallow, and waking brings a heaviness that takes time and hydration to dispel.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(15)
- Appetite enhancement— A distinct increase in hunger and desire for food, often accompanied by enhanced enjoyment of taste ...
- Changes in felt gravity— A distortion of one's proprioceptive sense of gravity in which the perceived direction of gravitatio...
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Dry mouth— A persistent, uncomfortable reduction in saliva production causing the mouth and throat to feel parc...
- Headache— A painful sensation of pressure, throbbing, or aching in the head that can range from a dull backgro...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Motor control loss— A distinct decrease in the ability to control one's physical body with precision, balance, and coord...
- Pain relief— A suppression of negative physical sensations such as aches and pains, ranging from dulled awareness...
- Perception of bodily heaviness— Perception of bodily heaviness is the subjective feeling that one's body has become dramatically hea...
- Perception of bodily lightness— Perception of bodily lightness is the subjective feeling that one's body has become dramatically lig...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Respiratory depression— A dangerous slowing and shallowing of breathing that can progress from barely noticeable reductions ...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Vasodilation— Vasodilation is the relaxation and widening of blood vessels, leading to increased blood flow, reduc...
Cognitive & Perceptual Effects
Cognitive(10)
- Analysis suppression— Analysis suppression is a cognitive impairment in which the capacity for logical reasoning, critical...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Depression— A persistent state of low mood, emotional numbness, hopelessness, and diminished interest or pleasur...
- Dream suppression— Dream suppression is a decrease in the intensity, frequency, and recollection of dreams — ranging fr...
- Mindfulness— Mindfulness in the substance context refers to a state of heightened present-moment awareness in whi...
- Paranoia— Irrational suspicion and belief that others are watching, plotting against, or intending harm toward...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Thought connectivity— A state in which disparate thoughts, concepts, and ideas become fluidly and spontaneously interconne...
- Thought deceleration— The experience of thoughts occurring at a markedly reduced pace, as if the mind has been placed into...
Pharmacology
Mechanism of Action
APICA is a full agonist at both CB1 andCB2 cannabinoid receptors. Full agonism at CB1 produces maximal receptor activation — unlike THC's partial agonism — resulting in a steep dose-response curve without the intrinsic efficacy ceiling that limits THC toxicity.
In Vivo Potency
Rat model studies have characterized APICA's potency relative to other synthetic cannabinoids: APICA showed potency similar to Δ9-THC and approximately one-third the potency of JWH-018 in standard cannabinoid tetrad assays. While this positions APICA as less potent than some synthetic cannabinoids, it remains far more potent than THC relative to the quantities present in herbal products, and full CB1 agonism ensures that higher doses produce physiological effects that THC cannot at any dose.
Adamantyl Group Pharmacology
The adamantyl (tricyclic cage structure) head group in APICA contributes to CB1/CB2 binding affinity through steric complementarity with the receptor binding pocket. Adamantyl-containing synthetic cannabinoids as a class have been characterized in research contexts and tend to produce high receptor occupancy at low doses.
Pharmacokinetics
Inhalation onset is rapid (seconds to minutes), producing a fast-peaking profile that increases compulsive re-administration risk. Oral onset is slower. Duration is typically 1–3 hours, though at higher doses effects may persist longer. Metabolic products of APICA have not been fully characterized.
Detection Methods
Standard Drug Panel Inclusion
APICA (SDB-001) is a synthetic cannabinoid receptor agonist that is not detected on standard 5-panel drug screens. Standard THC immunoassays target 11-nor-9-carboxy-THC (THC-COOH), the primary metabolite of delta-9-THC, and do not cross-react with synthetic cannabinoids. Some expanded drug panels (12-panel or custom panels) include a synthetic cannabinoid channel, but coverage of specific compounds varies widely between manufacturers.
Urine Detection
APICA (SDB-001) and its metabolites can be detected in urine for approximately 2 to 5 days after a single use, though chronic heavy use can extend this window to 7 or more days. Synthetic cannabinoids undergo extensive hepatic metabolism, primarily via hydroxylation and carboxylation, producing metabolites that are excreted in urine as glucuronide conjugates. The specific metabolite profile varies by compound and is a key factor in whether a given immunoassay can detect APICA (SDB-001).
Blood and Saliva Detection
Blood concentrations of APICA (SDB-001) decline rapidly after use, with a detection window of approximately 12 to 48 hours for the parent compound. Metabolites may persist longer. Oral fluid testing can detect parent compound and early metabolites for approximately 24 to 48 hours, and some roadside testing devices include synthetic cannabinoid panels.
Hair Follicle Detection
Hair follicle analysis can detect synthetic cannabinoids for up to 90 days. However, incorporation rates and detectability vary by compound. Some laboratories offer expanded hair panels that include common synthetic cannabinoids such as JWH-018 and AB-FUBINACA metabolites, but coverage of newer compounds including APICA (SDB-001) may be limited.
Confirmatory Testing
LC-MS/MS is the preferred confirmatory method for synthetic cannabinoids. The structural diversity and rapid evolution of this substance class means that reference standards must be available for the specific compound under investigation. GC-MS can also be used but LC-MS/MS offers superior sensitivity and specificity for the typically low concentrations encountered. Both parent compound and key metabolites should be targeted.
Reagent Testing
Standard reagent tests (Marquis, Mecke, Mandelin) are generally uninformative for synthetic cannabinoids, as these compounds are typically applied to herbal material at very low concentrations and produce no characteristic color reactions. Visual inspection and reagent testing cannot distinguish treated herbal material from untreated plant matter. Immunoassay-based test strips specific to synthetic cannabinoids are available from some harm reduction suppliers and represent a more practical point-of-use screening option.
Interactions
| Substance | Status | Note |
|---|---|---|
| 1,3-Butanediol | Caution | Cannabis can unpredictably intensify psychedelic effects and increase anxiety |
| 1,4-Butanediol | Caution | Increased sedation and cognitive impairment |
| 1B-LSD | Caution | Cannabis can unpredictably intensify psychedelic effects and increase anxiety |
| 1cP-AL-LAD | Caution | Cannabis can unpredictably intensify psychedelic effects and increase anxiety |
| 1cP-LSD | Caution | Cannabis can unpredictably intensify psychedelic effects and increase anxiety |
History
Development and Market Entry
APICA appeared in the synthetic cannabinoid market in the early 2010s, initially in Japan and subsequently across Europe and North America. The adamantyl head group was a novel structural feature at the time, contributing to early regulatory uncertainty before the compound was specifically identified and scheduled.
Legal Control
APICA has been scheduled in multiple jurisdictions, including the United States (DEA Schedule I, 2014 temporary order, subsequently permanent), Japan, and most European nations. Like other synthetic cannabinoids, scheduling has been followed by replacement with structural analogs.
Harm Reduction
Avoid Synthetic Cannabinoids
The safest harm-reduction position is complete avoidance of synthetic cannabinoid products. If harm reduction for users who choose to use is the goal:
- Use in the presence of others who know what was consumed
- Begin with the smallest possible inhalation (single short puff)
- Wait 15–20 minutes before further use — inhalation onset is rapid
- Avoid mixing with depressants or stimulants
- Have emergency contact information available
Product Labeling Is Unreliable
Products sold as "spice," "K2," or herbal blends may contain APICA or any of dozens of synthetic cannabinoids. Product labeling is not regulated and frequently inaccurate. Reagent testing cannot reliably identify specific synthetic cannabinoids in mixtures.
Emergency Response
Seizures, chest pain, loss of consciousness, irregular heartbeat, or severe psychiatric symptoms require immediate emergency response. Inform medical personnel of the substance class.
Toxicity & Safety
Full Agonist Toxicity
APICA shares the full synthetic cannabinoid toxicity profile: cardiovascular events (tachycardia, arrhythmia, myocardial stress), seizures, acute psychotic episodes, renal complications, and respiratory depression at high doses. These effects are qualitatively different from cannabis toxicity and can manifest at doses that produce only mild-to-moderate intoxication in experienced users due to the full agonism.
Psychotic Episodes
Indole carboxamide synthetic cannabinoids are documented in emergency medicine literature as causes of acute psychotic episodes. These episodes may include paranoid ideation, formal thought disorder, aggression, and hallucinations. While typically resolving with supportive care, persistent psychosis following synthetic cannabinoid exposure has been documented, particularly in individuals with vulnerability to psychosis.
Unknown Long-Term Profile
APICA's long-term toxicity in humans has not been studied. Chronic CB1 activation at the potency levels achievable with full agonists may produce receptor downregulation, tolerance, and dependence more severe than with cannabis, but specific data are lacking.
Addiction Potential
moderately addictive with a high potential for abuse
Overdose Information
Fatal overdose from natural cannabis (THC) alone has not been documented. However, synthetic cannabinoids can cause life-threatening overdose, and even natural cannabis can produce acute medical events requiring attention.
Natural cannabis — acute adverse reactions:
- Severe anxiety/panic attacks
- Transient psychotic episodes (paranoia, hallucinations)
- Vasovagal syncope (fainting)
- Tachycardia (rarely, cardiac events in predisposed individuals)
- Cannabis Hyperemesis Syndrome (cyclic severe vomiting with chronic heavy use)
Synthetic cannabinoid overdose (medical emergency):
- Seizures, loss of consciousness
- Severe agitation or psychosis
- Chest pain, rapid irregular heartbeat
- Difficulty breathing
- Acute kidney injury
Response: For natural cannabis adverse reactions, reassurance and a calm environment usually suffice ("you're safe, this will pass"). For synthetic cannabinoid emergencies, call emergency services immediately.
Tolerance
| Full | develops with prolonged and repeated use |
| Half | 3 - 7 days |
| Zero | 1 - 2 weeks |
Cross-tolerances
Legal Status
China: As of October 2015 APICA is a controlled substance in China.
Germany: APICA is controlled under Anlage II BtMG (Narcotics Act, Schedule II) as of December 13, 2014. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
Switzerland: APICA is a controlled substance specifically named under Verzeichnis E.
United Kingdom: APICA is a Class B controlled substance under the third-generation synthetic cannabinoids generic definition, which came into effect on December 14, 2016 and is illegal to possess, produce, supply, or import.
Responsible use
Designer drug
Synthetic cannabinoids
AKB48
STS-135
APICA (Wikipedia)
APICA (Isomer Design)
2NE1 (N-adamantyl-1-pentylindole-3-carboxamide) Drug Info (Drugs-Forum)
Tips (5)
Dose APICA extremely conservatively. Synthetic cannabinoids are active at much lower doses than THC and potency varies enormously between batches. A dose that was mild from one batch could be dangerously strong from another.
Test any batch of APICA cautiously. Take only a tiny amount initially and wait at least 30 minutes to assess effects. The variability between batches makes every new batch effectively a first-time experience.
Synthetic cannabinoids like APICA are far more dangerous than natural cannabis. They are full agonists at CB1 receptors, producing much stronger effects with a higher risk of seizures, psychosis, and organ damage.
Never mix APICA with other substances, especially depressants or stimulants. Synthetic cannabinoids have unpredictable pharmacology and interactions can be severe, including cardiac events and seizures.
Consider whether the risk of APICA is worth it compared to natural cannabis where available. Synthetic cannabinoids were created to evade drug tests and laws, not because they are better or safer than cannabis.
See Also
References (3)
- PubChem: APICA
PubChem compound page for APICA (CID: 71308155)
pubchem - APICA - TripSit Factsheet
TripSit factsheet for APICA
tripsit - APICA - Wikipedia
Wikipedia article on APICA
wikipedia